FATE Fate Therapeutics
- 3.410
- -0.160-4.48%
Fate Therapeutics News
Fate Therapeutics Drops To US$3.41, Yet Insiders May Have Sold Too Early
Even though Fate Therapeutics, Inc. (NASDAQ:FATE) has fallen by 12% over the past week , insiders who sold US$222k worth of stock over the past year have had less luck. Insiders might have been bette
Expert Outlook: Fate Therapeutics Through The Eyes Of 9 Analysts
Across the recent three months, 9 analysts have shared their insights on Fate Therapeutics (NASDAQ:FATE), expressing a variety of opinions spanning from bullish to bearish.The following table encapsul
This Best Buy Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings pag
Express News | Fate Therapeutics Shares Are Trading Higher After Piper Sandler Upgraded the Stock From Neutral to Overweight and Raised Its Price Target From $4 to $6
Piper Sandler Upgrades Fate Therapeutics(FATE.US) to Buy Rating, Raises Target Price to $6
Piper Sandler analyst Edward Tenthoff upgrades $Fate Therapeutics(FATE.US)$ to a buy rating, and adjusts the target price from $4 to $6.According to TipRanks data, the analyst has a success rate of 0.
Express News | Fate Therapeutics Inc : Piper Sandler Raises Target Price to $6 From $4
Express News | Fate Therapeutics Inc : Piper Sandler Raises to Overweight From Neutral
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, June 04, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent
Fate Therapeutics CFO Resigns, CEO to Assume Role
Express News | Fate Therapeutics Inc - Board Intends to Appoint J. Scott Wolchko to Succeed Dulac as Chief Financial Officer
Express News | Fate Therapeutics Inc - on May 30, Edward J. Dulac III Provided Notice of His Resignation From His Position as Chief Financial Officer
Fate Therapeutics to Present at 2024 Jefferies Global Healthcare Conference
SAN DIEGO, May 29, 2024 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the "Company" or "Fate Therapeutics") (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in
Alibaba To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.Stifel cut
Fate Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
Fate Therapeutics Is Maintained at Neutral by HC Wainwright & Co.
Analysts' Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), Acumen Pharmaceuticals (ABOS) and DENTSPLY SIRONA (XRAY)
Fate Therapeutics: Advancements and Differentiation in Autoimmune and Cancer Therapies Support Buy Rating
Express News | Fate Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $5 From $7
Stifel Nicolaus Sticks to Their Hold Rating for Fate Therapeutics (FATE)
Hold Rating on Fate Therapeutics Amid Pending Clinical Data and Strategic Pipeline Focus
Fate Therapeutics: A Promising Contender in Autoimmune Disease Cell Therapy With Innovative FT819 and FT522 Trials
Analysis
Price Target
No Data
